Ligand Pharmaceuticals | LGND - Trade Creditors


Ligand Pharmaceuticals reported $27.76M in Trade Creditors for its fiscal quarter ending in September of 2025.





Trade Creditors Change Date
Agenus USD 85.29M 10.89M Sep/2025
Amgen USD 20.89B 1.25B Dec/2025
Anika Therapeutics USD 4.73M 39K Sep/2025
Arrowhead Research USD 32.94M 15.26M Dec/2025
Baxter International USD 999M 46M Dec/2025
Bristol-Myers Squibb USD 4.29B 1.14B Sep/2025
Eli Lilly USD 5.38B 1.12B Dec/2025
Enanta Pharmaceuticals USD 1.88M 63K Dec/2025
Enviri Corporation USD 250.64M 9.89M Sep/2025
Gilead Sciences USD 808M 226M Sep/2025
GlaxoSmithKline GBP 15.38B 294M Dec/2025
Glaxosmithkline GBP 21.07B 7.42B Sep/2025
Heron Therapeutics USD 12.02M 20K Sep/2025
Insmed USD 79.91M 316K Dec/2025
Intrexon USD 4.85M 3.12M Jun/2024
Ionis Pharmaceuticals USD 14.33M 8.47M Sep/2025
Karyopharm Therapeutics USD 5.39M 2.8M Sep/2025
Ligand Pharmaceuticals USD 27.76M 1.72M Sep/2025
MacroGenics USD 5.94M 1.28M Sep/2025
Merck USD 4.15B 102M Sep/2025
Pacira USD 17.69M 12.44M Sep/2025
Pfizer USD 5.02B 142M Sep/2025
Rigel Pharmaceuticals USD 3.85M 3.44M Sep/2025
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Veracyte USD 4.59M 916K Dec/2025